Skip to content
About
About Us
Our Team
Publications
Research
Project 3 – Pancreas ADM
Project 4 – Lung
Pilot Project 5 – Pancreas
Cycle 1 (2018-2023)
Project 1 – Prostate
Project 2 – Pancreas
Pilot Project 1 – Pancreas
Pilot Project 2 – Prostate
Pilot Project 3 – Lung
Pilot Project 4 – Pancreas
Education
Summer-CaRE2 Training Program
Postbac-CaRE2 Training Program
Grad+ CaRE2
Outreach & Engagement
The CaRE2 Contact Registry
Community Scientist Program
Cancer Education Programs
Cancer Information and Education Materials
Resources
Developmental Research Projects Awards
Tissue Modeling & Drug Development Core
Bioinformatics, Statistical & Methodological Core
Planning & Evaluation
News & Events
Contact
Menu
About
About Us
Our Team
Publications
Research
Project 3 – Pancreas ADM
Project 4 – Lung
Pilot Project 5 – Pancreas
Cycle 1 (2018-2023)
Project 1 – Prostate
Project 2 – Pancreas
Pilot Project 1 – Pancreas
Pilot Project 2 – Prostate
Pilot Project 3 – Lung
Pilot Project 4 – Pancreas
Education
Summer-CaRE2 Training Program
Postbac-CaRE2 Training Program
Grad+ CaRE2
Outreach & Engagement
The CaRE2 Contact Registry
Community Scientist Program
Cancer Education Programs
Cancer Information and Education Materials
Resources
Developmental Research Projects Awards
Tissue Modeling & Drug Development Core
Bioinformatics, Statistical & Methodological Core
Planning & Evaluation
News & Events
Contact
FDA Approval
By
Jose Aparicio
December 2, 2021
We are excited to announce that Tissue Modeling Core Co-Leader Dr Paul Okunieff and the company he founded DiaCarta have received FDA approval for their Covid-19 Test that is able to detect covid-19 variants using an algorithm they developed.
https://www.prnewswire.com/news-releases/diacartas-multivariant-covid-19-test-accurately-detects-the-omicron-variant-301434105.html?tc=eml_cleartime
Facebook
Twitter
LinkedIn
Pinterest